Core Viewpoint - Shenzhen Huitai Medical Equipment Co., Ltd. has approved a share repurchase plan to enhance investor confidence and establish a long-term incentive mechanism [1] Group 1: Share Repurchase Plan - The company plans to use its own funds to repurchase part of its A-shares through centralized bidding, with a total repurchase amount not less than RMB 150 million and not exceeding RMB 200 million [1] - The maximum repurchase price is set at RMB 315 per share, and the repurchase period is within 10 months from the board's approval date [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives, and if not fully transferred within three years, they will be legally canceled [1] Group 2: Financial Position - As of September 30, 2025, the company's total assets are approximately RMB 3.461 billion, and the net assets attributable to shareholders are about RMB 2.989 billion [1] - Based on the upper limit of the repurchase funds, the repurchase amount accounts for approximately 6.69% of the net assets [1] Group 3: Impact and Confidence - The company believes that the repurchase will not significantly impact its daily operations, finances, or future development, nor will it lead to a change in control or affect its listing status [1] - The decision is based on confidence in the industry outlook and the company's future development [1]

Group 1 - Jinwei Co., Ltd. plans to acquire 100% equity of Fusheng Mining for 210 million yuan, which will become a wholly-owned subsidiary and included in the consolidated financial statements [2] - Mengguli intends to invest 929 million yuan to build a project with an annual production capacity of 30,000 tons of lithium-ion battery cathode materials, expected to produce 5,000 tons of high-voltage cobalt acid lithium, 10,000 tons of NCA materials, and 15,000 tons of ultra-high nickel ternary materials [2] - Xiamen Tungsten plans to acquire 39% equity of Jiujiang Dadi Mining, which will help increase mineral resource reserves and improve raw material self-sufficiency [3] Group 2 - Andavil's subsidiary received EASA certification for its aviation kitchen plug-in products, marking compliance with European aviation safety standards [2] - CIMC Vehicles disclosed that the US ITC made a preliminary ruling on anti-subsidy and anti-dumping investigations regarding Van-Type Trailers, indicating potential damage to the US domestic industry [4] - Source Technology plans to invest approximately 1.251 billion yuan to build a second phase project for the R&D and production of optoelectronic communication semiconductor chips and devices [9] Group 3 - Zhongmin Energy intends to acquire 51% equity of Mintou Pumped Storage for 864 million yuan, with the transaction price based on asset evaluation [10] - Ningbo Yunsheng plans to publicly issue H-shares and apply for listing on the Hong Kong Stock Exchange [11] - Wenkai Co., Ltd. won a bid for a landscape project worth 50.8162 million yuan [12] Group 4 - China Merchants Shekou achieved a signed sales amount of 7.674 billion yuan in January 2026 [16] - AVIC Optoelectronics reported a net profit of 2.124 billion yuan for 2025, a year-on-year decrease of 36.69% [17] - Tiankang Bio reported a sales revenue of 392 million yuan from pig sales in January 2026, with a month-on-month increase of 6.23% [18] Group 5 - Poly Developments reported a signed amount of 15.617 billion yuan in January 2026, a year-on-year decrease of 13.31% [19] - Chengtou Holdings reported a net profit of 290 million yuan for 2025, a year-on-year increase of 19.67% [20] - Qianjin Pharmaceutical reported a net profit of 288 million yuan for 2025, a year-on-year increase of 24.74% [21]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

惠泰医疗(688617.SH)发布公告，公司拟1.5亿元至2亿元回购股份，回购股份价格不超过315元/股，回购 的股份将在未来适宜时机用于员工持股计划或股权激励。 ...

智通财经APP讯，惠泰医疗(688617.SH)发布公告，公司拟1.5亿元至2亿元回购股份，回购股份价格不超 过315元/股，回购的股份将在未来适宜时机用于员工持股计划或股权激励。 ...

北京商报讯（记者 丁宁）2月9日晚间，惠泰医疗（688617）发布公告称，基于对行业前景和公司未来 发展的信心，以及对公司长期投资价值的认可，为了维护广大投资者利益，增强投资者对公司的投资信 心，同时为了进一步建立健全公司长效激励机制，促进公司健康可持续发展，公司拟以自有资金通过上 交所交易系统以集中竞价交易方式回购部分公司股票，并在未来适宜时机将回购股份全部用于员工持股 计划或股权激励，回购资金总额不低于1.5亿元（含），不超过2亿元（含）。 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-004 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司 关于以集中竞价交易方式回购股份方案 暨回购报告书 重要内容提示： ● 回购股份金额：回购资金总额不低于人民币1.5亿元（含），不超过人民币 2亿元（含）。 ● 回购股份资金来源：自有资金 ● 回购股份用途：本次回购的股份将在未来适宜时机用于员工持股计划或股 权激励，并在公司披露股份回购实施结果暨股份变动公告日之后的三年内予以转 让；若公司本次回购的股份未能在上述三年内转让完毕，公司将依法履行减少注 册资本的程序，未转让股份将予以注销。如国家对相关政策作出调整，则本回购 方案按调整后的政策实行。 ● 回购股份价格：不超过人民币315元/股（含），该价格不高于公司董事会 通过回购决议前30个交易日公司股票交易均价的150%。 ● 相关股东是否存在减持计划： 公司董事、高级管理人员、控股股东、实际控制人及一致行动人、持股 5%以上 的股东在董事会通过回购决议之日的未来3个月、未来6 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-003 特此公告。 深圳惠泰医疗器械股份有限公司董事会 深圳惠泰医疗器械股份有限公司（以下简称"公司"）第三届董事会第三次 会议通知于 2026 年 2 月 9 日发出并送达全体董事，全体董事同意豁免本次会议 的提前通知时限要求。本次会议于 2026 年 2 月 9 日以现场结合通讯方式召开， 会议应到董事 9 人，实到董事 9 人，出席董事占应出席人数的 100%。本次会议 的召集、召开及表决程序符合《中华人民共和国公司法》等有关法律、行政法规、 规范性文件和《深圳惠泰医疗器械股份有限公司章程》的规定，会议决议合法有 效。经与会董事审议和表决，会议形成决议如下： 一、 审议通过《关于以集中竞价交易方式回购股份方案的议案》 董事会认为，本次回购公司股份方案设计合理，有利于维护广大投资者利益， 增强投资者对公司的投资信心，建立健全公司长效激励机制，促进公司健康可持 续发展，全体董事一致同意该事项。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《深 圳惠泰医疗器械股份有限公司关于以集中竞价交易方式回购股份方案暨回购报 ...

每经AI快讯，惠泰医疗2月9日晚间发布公告称，公司第三届董事会第三次会议于2026年2月9日以现场 结合通讯方式召开。会议审议了《关于以集中竞价交易方式回购股份方案的议案》。 每经头条（nbdtoutiao）——美国名校毕业刚回国，26岁"金少"空降成董事长和总经理，父母隐退！A股 多位"00后"执掌要职，"不负投资者"成重大考验 （记者 张明双） ...

每经AI快讯，2月9日，惠泰医疗(688617.SH)公告称，公司计划通过集中竞价交易方式回购股份，资金 总额不低于1.5亿元，不超过2亿元，用于员工持股计划或股权激励。回购价格不超过315元/股，期限为 自董事会审议通过之日起10个月内。公司董事、高级管理人员、控股股东等在未来3个月、6个月无明确 的减持计划。 ...